Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCT-517
- Development stage
- Preclinical
- Lead developer
- Canary Cure
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
CCT-517 is an investigational small interfering RNA (siRNA) therapeutic developed by Canary (Canary Cure) for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The drug is designed to promote the browning of white adipose tissue (WAT) and provide metabolic protection, thereby increasing energy expenditure and improving metabolic health. Developed using Canary's "Reprogram Platform," which combines AI-driven target selection with siRNA technology, CCT-517 is currently in the IND-enabling phase of development. The platform aims to identify novel targets that can reprogram adipose tissue to enhance thermogenesis, offering a potential long-acting treatment for metabolic disorders.
02
Targets
ZNF423 (Zinc finger protein 423)
Beyond the preview
Go deeper on CCT-517.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCT-517.